Progenicyte Therapeutics

Focus: Progenicyte Therapeutics is a newly founded (2024) Chicago-based biotech specializing in stem cell and cell/gene therapies with an established product portfolio including diagnostic and therapeutic radiopharmaceuticals.

Cell Therapy Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Progenicyte Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Progenicyte Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

PYLARIFY

Prostate cancer imaging (PSMA-targeted PET)

Peak11.1yr

Core diagnostic asset with 13+ years of exclusivity, targeting high-value oncology imaging market with recurring hospital/clinic utilization.

Help build intelligence for Progenicyte Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage company with established FDA-approved products (PYLARIFY, AZEDRA) providing immediate revenue and credibility rather than pure pre-clinical risk
Opportunity to shape clinical and commercial strategy from inception in a high-growth cell therapy segment with significant unmet patient needs
Presence of marketed therapeutics in oncology (prostate cancer, neuroendocrine tumors) offers exposure to specialty pharma realities alongside biotech innovation

Watch Out For

Zero active clinical trials and empty pipeline suggest company may be acquired assets or transitional entity with unclear independent R&D agenda
No disclosed funding, headcount, or hiring activity (0 active job postings) creates uncertainty about actual operational scale and growth runway

Generated by Claude from Progenicyte Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PYLARIFY TRUVU

Prostate cancer imaging (PSMA-targeting radiopharmaceutical)

Launch

Recently launched companion product with extended indication or formulation, representing near-term commercial growth catalyst.

AZEDRA

Neuroendocrine tumors

Peak

Established therapeutic radiopharmaceutical in specialty oncology, likely acquired asset with mature market position.